Dentsply Sirona stock faces weaker Q3 and lower 2026 outlook

Published on 11/12/2026 at 14:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dentsply Sirona stock is under scrutiny after third-quarter sales fell to $836 million. Management lowered its adjusted EPS outlook for 2026.

Quarterly pressure meets a cautious outlook

Management expects full-year adjusted EPS of $1.20 to $1.30, excluding a one-time tariff-refund benefit.
Wellspect Healthcare delivered record quarterly sales and 10.1% reported growth.
A $39 million inventory-accounting benefit supported reported gross profit but is not expected to recur.

XRAY, US24906P1093, Illustration mit AI erstellt.

Dentsply Sirona reported third-quarter 2026 results on Thursday, November 5, with net sales down 7.6% year over year to $836 million. The dental products maker also narrowed its full-year outlook to approximately $3.5 billion in sales and adjusted earnings per share of $1.20 to $1.30. The company released the figures in its quarterly results release.

Sales weakness weighs on guidance

Reported sales declined across three of the four operating segments. Connected Technology Solutions revenue fell to $230 million, Essential Dental Solutions revenue reached $343 million, and Orthodontic and Implant Solutions revenue was $171 million. Wellspect Healthcare was the exception, with record quarterly sales of $92 million and 10.1% reported growth.

Management said the quarter included pressure from lower dental volumes, the absence of Byte revenue and planned distributor inventory reductions. Sales declined 7.0% on a constant-currency basis, a non-GAAP measure that removes the effect of currency movements.

One-time benefit clouds earnings quality

Dentsply Sirona reported adjusted EPS of $0.29, compared with $0.42 a year earlier. Gross profit included a $39 million benefit from refining the estimate used to eliminate unrealized profit in inventory. The company said the adjustment reduced the reported net loss by approximately $30 million and equivalent benefits are not expected in future periods.

For 2026, the updated adjusted EPS outlook excludes a $0.17 one-time benefit from tariff refunds. The revision leaves the sales target at the lower end of the previous range while reducing the adjusted EPS range from $1.40 to $1.50.